Mata da maimaita UTIs za su amfana
Samun sha'awa a maganin rigakafi na UTI an hura a cikin shekarun 1950, kuma tun daga wannan lokacin, masu bincike sun nema maganin rigakafin da zai iya hana kwayoyin E. coli daga canzawa da mafitsara kuma don haka farawa kamuwa da cuta. A cikin watan Yulin 2017, FDA ta ba da ilimin kimiyyar Sequoia 'FimCH UTI maganin rigakafi. Idan an yarda, cutar ta FimCH za ta kasance ta farko na allurar rigakafi don UTI samuwa a Amurka.
A cewar FDA:
Tsarin sauri shine tsarin da aka tsara don sauƙaƙe ci gaban, kuma ya gaggauta nazarin magungunan don magance matsalolin da ya dace kuma ya cika buƙatar rashin lafiya. Dalilin shi ne don samun magungunan sababbin magunguna zuwa ga masu haƙuri a baya. Adireshin Saurin adana adireshi mai tsanani.
Bayani
An sami karuwa a yawan adadin kwayoyin kwayoyin cuta wanda ke haifar da cututtuka na urinary mai tsanani (UTIs) . Tare da UTI, kamuwa da cuta zai iya tashi daga mafitsara (cystitis) cikin kodan (pyelonephritis). Wadannan cututtuka na iya kara yada cikin jini da ke haifar da sepsis . Kwayar cututtuka, asibiti, har ma da mutuwa mutuwa ne sakamakon mummunar cutar UTI.
Dangane da wannan barazana ga lafiyar mutum da lafiyar jama'a, an sami gagarumin sha'awar bunkasa maganin alurar rigakafi don hana rigakafin kwayoyin cutar UTI kuma ta haka ne ya hana bukatar maganin maganin rigakafi na ƙarshe-yin amfani da abin da ke ci gaba da yalwata ƙarancin juriya na kwayoyin halitta .
Bugu da ƙari, maganin rigakafin UTI zai iya taimakawa ciwo da rashin jin daɗi na mata waɗanda suka sami UTI-musamman ma wadanda ke shan wahala daga maimaitawa, ko na yau da kullum, UTIs - hakan yana inganta rayuwar mutane miliyoyin.
Fimch Vaccine
Cutar rigakafin FimCH wani maganin rigakafin antigen ne kawai wanda ya ƙunshi furotin na FimH na maganin kwayar cutar.
Hanyoyin FimH wajibi ne don E. coli ya mallaki urinary fili. Alurar rigakafi yana haifar da amsawar rigakafi don ƙaddamar da tsarin FimH.
Saboda cigaba a tsarkakewar sinadaran da ci gaba da fasaha na DNA na recombinant, idan aka kwatanta da allurar kwayoyin halitta, ƙwayoyin maganin antigen ne suka zama sanannun a cikin 'yan shekarun nan. Bugu da ƙari, ƙwayoyin maganin antigen na musamman za'a iya haɗuwa.
Ana amfani da antigens da aka yi amfani da wadannan maganin a cikin ɗayan hanyoyi biyu. Na farko, masu bincike zasu iya yin amfani da tsarin salula (watau, cikin vivo) ko dabba. Na biyu, ta yin amfani da maganin rigakafi, masu bincike na iya hango hangen nesa da magungunan antigens. An gano maganin rigakafin FimCH ta amfani da samfurin dabba.
Kwayar cutar FimCH ba sabon ba ne. An samo lasisi daga Madammun kuma ya shiga kashi na I da na II na gwajin gwaji kafin a bar shi daga ci gaba. Abin mahimmanci, an yi maganin alurar rigakafi a lokacin gwaji na gwaje-gwaje. Bayanan Sequioa sa'an nan kuma lasisi alurar riga kafi, canza adjuvant, kuma ya shiga gwaji na asibiti. An adjuvant an dakatar da shi da aka tsara tare da maganin alurar riga kafi kuma an yi amfani da ita wajen bunkasa amsawa.
Na bayanin kula, lokuta na gwajin gwaji ne binciken da ke tattare tsakanin mambobi 20 zuwa 100 don gwada lafiyar da maganin miyagun ƙwayoyi.
Sakamakon na II na gwajin gwagwarmayar gwaje-gwaje har zuwa yawancin masu halartar da dama kuma bincika tasiri da kuma mummunan tasirin magani. Sakamakon gwaje-gwaje na Phase III zai iya hada da dubban mahalarta kuma yayi nazari akan inganci da kuma saka idanu don tasiri.
A cewar rahotanni na jarida, lokacin gwajin FimCH na lokacin Sequoia, an yi maganin alurar riga kafi kuma ya haifar da amsa mai karfi. Fiye da haka, mata 67 sun sami maganin alurar riga kafi. Daga cikin wadannan mata, 30 suna da tarihin mawuyacin hali na UTI wanda ya kasance shekaru 2. Musamman, sakamakon wannan lokaci na gwajin gwaji ba a buga su ba a cikin wallafe-wallafen.
Wanene Ya Kamata Samun Lura?
Mata da ke kwarewa UTI sune masu kirki ne don maganin rigakafin UTI.
Cystitis, ko kuma kamuwa da cuta mai mafitsara, ya kai kimanin kashi 90 cikin 100 na dukkanin UTIs. Tsakanin kashi 20 zuwa 30 cikin dari na matan nan suna samun komawa cikin watanni 3 ko 4. Sauran ƙwayoyin UTI suna haifar da rashin jin daɗi da kuma ciwo kuma suna taimakawa wajen maganin kwayoyin cutar saboda matan da suke da su sukan dauki maganin rigakafi a cikin yawancin shekarar.
Shin An Yi Gwada Sauran Cutar Lura Kan Kwanan nan?
GlycoVaxyn da Janssen Pharmaceuticals sunyi aiki a kan wata rigakafi ta UTI da ake kira ExPEC4V, wanda shine dan takarar mai maganin alurar rigakafin E. coli. A watan Fabrairun 2017, Huttner da masu marubuta sun saki binciken daga gwajin gwaji na wannan maganin asibiti.
A cikin duka, mata 93 suka sami maganin alurar riga kafi kuma mata 95 sun sami wuri. Mahalarta sun kasance tsakanin shekarun 18 zuwa 70 da kuma suna da tarihin mawuyacin UTI. Alurar rigakafin da aka samu ya karɓa ta hanyar masu karɓa. Bugu da ƙari kuma, maganin ya haifar da wata amsa mai mahimmanci, kuma matan da suka sami maganin sun kasance marasa ƙarancin UTI da E. coli ya haifar.
A ƙarshe, a lokacin gwaji na asibiti, rigakafin FimCH ya nuna alƙawari a kan hana UTI da E. coli ya haifar. A halin yanzu, yanke shawara game da amincewa da maganin wannan maganin yana amfani da ita ta FDA. Idan an yarda, wannan maganin alurar rigakafi zai hana kwayoyin-resistant UTIs kuma za su kasance musamman taimako ga mata tare da maimaita UTIs.
> Sources:
> FDA. Fast hanya. www.fda.gov
> Gupta K, Trawler BW. Magungunan Tracton Urinary, Pyelonephritis, da Prostatitis. A: Kasper D, Fauci A, Hauser S, Longo D, Jameson J, Loscalzo J. eds. Ka'idodin Magunguna na Harrison, 19th New York, NY: McGraw-Hill.
> Huttner, A, et al. Tsaro, immunogenicity, da kuma magunguna na farko na maganin maganin alurar rigakafi da cututtuka na asibiti Escherichia coli a cikin mata tare da tarihin ciwon urinary mai ciwon kamuwa da cuta mai ma'ana, makãho, makirci mai gudanarwa na lokaci 1b. Cututtuka na Lancet cututtuka. 2017; 17 (5): 528-537.
> O'Brian, VP, et al. Drug da Vaccine Development for Treatment da Rigakafin ƙwayar cutar Urinary Tract. Microbiology Spectrum. 2016.